Priority 2 from the Multiple Sclerosis PSP

UNCERTAINTY: How can multiple sclerosis be prevented? (JLA PSP Priority 2)
Overall ranking 2
JLA question ID 0016/2
Explanatory note No relevant systematic reviews identified

No evidence found

Systematic reviews that need extending or updating

No reviews found

Systematic reviews in preparation

No reviews found

Ongoing controlled trials

Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome D-Lay-MS NCT01817166

Dose-related effects of Vitamin D3 on immune responses in patients with clinically isolated syndrome CISAVID NCT01728922

Health Research Classification System category Neurological
Extra information provided by this PSP
Original uncertainty examples No examples provided.  This is an indicative uncertainty and several submissions were merged to form this one. 
Submitted by 16 patients ~ 8 carers ~ 7 clinicians
Outcomes to be measured Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
PSP information
PSP unique ID 0016
PSP name Multiple Sclerosis
Total number of uncertainties identified by this PSP. 82  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop July 2013